BPC-157 — compound monograph
Synthetic pentadecapeptide derived from a gastric juice protein sequence. Unapproved, research supply. The Institute assesses 4 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- BPC-157
- Compound class
- Synthetic pentadecapeptide derived from a gastric juice protein sequence
- Assessment series
- Repair and regeneration
- Synonyms and codes
- Bepecin · PL 14736 · pentadecapeptide BPC 157 · body protection compound 157
- Route as evaluated
- Subcutaneous, intraperitoneal or oral in preclinical studies; subcutaneous or oral in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Average mass
- 1419.53
- Monoisotopic mass
- 1418.72
- ATC classification
- not assigned
§1.3Sequence and structural notes
A 15-residue partial sequence corresponding to residues 14–28 of human gastric juice protein BPC. The GEPPPGKPADDAGLV sequence contains a triproline motif that confers unusual conformational rigidity and resistance to enzymatic degradation, and no cysteine, methionine or tryptophan — which makes it one of the analytically simplest peptides in this series and correspondingly one of the easiest to make well.
§1.4Assessment status
The Institute assesses BPC-157 across 4 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for BPC-157, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Cutaneous wound healing and tissue repair | No randomised controlled human trial identified | Very low | 0 |
| Inflammatory bowel disease and mucosal barrier disorders | A phase 2 programme in ulcerative colitis was conducted and results were not published in a peer-reviewed journal in a form the Institute could verify | Very low | 1 |
| Knee osteoarthritis with obesity | No randomised controlled human trial identified | Very low | 0 |
| Tendon, ligament and musculoskeletal soft-tissue injury | No randomised controlled human trial identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.